The effect of resveratrol on PCOS
Phase 3
- Conditions
- polycystic ovary syndrome.polycystic ovarian syndrome
- Registration Number
- IRCT2017061917139N2
- Lead Sponsor
- EMRI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 80
Inclusion Criteria
PCOS diagnosis (according to Androgen Excess Society criteria); hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone >70ng/dl) and/or oligomenorrhea (<8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound
Women aged from 18 to 40 years old; Normal prolactin; normal thyroid function; 17-OH progesterone; No evidence of Androgenic hormone secretor tumors; Cushing's syndrome or acromegaly
Exclusion criteria:
Use of either oral contraceptives, steroids hormones or other medications that could modify the metabolism 3 months before the onset of the trial.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (S.H.B.G) Sex Hormon Binding Globolin. Timepoint: Before and 12 weekes after the intervention. Method of measurement: -.;FSH. Timepoint: Before and 6 weekes after the intervention. Method of measurement: ng/ml.;LH. Timepoint: Before and 6 weekes after the intervention. Method of measurement: ng/ml.;Fasting blood sugar. Timepoint: Before and 6 weekes after the intervention. Method of measurement: mg/dl.;Testosterone. Timepoint: Before and 12 weekes after the intervention. Method of measurement: ng/ml.;DHEA-S. Timepoint: Before and 12 weekes after the intervention. Method of measurement: nmol/L.
- Secondary Outcome Measures
Name Time Method